Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced the completion of its previously announced merger with ARCA biopharma, Inc. The combined company will operate under the name Oruka Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Global Market today, September 3, 2024, under the ticker symbol "ORKA". In addition, Oruka announced the appointment of Samarth Kulkarni, PhD, current Chairman and CEO of CRISPR Therapeutics, as Chairman of Oruka's Board of Directors.
Concurrent with the merger, Oruka completed a previously announced $275 million private placement with a syndicate of new and existing investors including Fairmount, Venrock Healthcare Capital Partners, RTW Investments, Access Biotechnology, Commodore Capital, Deep Track Capital, Perceptive Advisors, Blackstone Multi-Asset Investing, Avidity Partners, Great Point Partners LLC, Paradigm BioCapital, Braidwell LP and Redmile Group, along with multiple large investment management firms. Following the merger, private placement, and reverse stock split, there are approximately 46.3 million shares of the combined company's common stock and common stock equivalents outstanding, including shares of common stock underlying pre-funded warrants and Series B non-voting convertible preferred stock, and excluding employee and director equity.
バイオテクノロジー企業であるOruka Therapeutics, Inc.（「Oruka」）（NASDAQ:ORKA）は、新規バイオロジクスを開発し、さまざまな慢性皮膚疾患、結節性乾癬を含む治療の新基準を確立することを目指しています。本日、2024年9月3日、OrukaはARCA biopharma, Inc.との合併を完了し、合併会社はOruka Therapeutics, Inc.として運営され、その株は本日Nasdaq Global Marketで取引が開始され、歩み値が「ORKA」になります。さらに、OrukaはCRISPR Therapeuticsの現在の会長兼CEOであるSamarth Kulkarni, PhDを取締役会の議長に任命しました。
合併に伴い、OrukaはFairmount、Venrock Healthcare Capital Partners、RTW Investments、Access Biotechnology、Commodore Capital、Deep Track Capital、Perceptive Advisors、Blackstone Multi-Asset Investing、Avidity Partners、Great Point Partners LLC、Paradigm BioCapital、Braidwell LP、Redmile Groupを含む新規および既存の投資家シンジケートと275百万ドルの非公募発行を完了しました。合併、非公募発行、逆株式分割を経て、合併会社の普通株式および普通株式に相当する発行済株式は約4630万株あり、それには事前資金調達ワラントと非議決権付きシリーズb転換型優先株式を含むが、従業員および取締役の株式は含まれていません。
